Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 13, 2026
Reporting Period: Fiscal quarter ended March 31, 2026
Context: The filing announces the issuance of a press release containing financial results for the specified period. The press release is attached as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided Form 8-K text serves as a cover document referencing a press release (Exhibit 99.1) but does not contain specific financial data. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide comparative data or specific details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
Guidance and Outlook: No specific guidance or management commentary is included in the Form 8-K text itself.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information (including the press release) is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 13, 2026) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical or operational milestones achieved during the quarter ended March 31, 2026, as these are not detailed in the 8-K summary.
- Confirm the company's cash runway and burn rate from the full press release to assess liquidity risks.
- Check for any updates on regulatory filings or trial data that may have been announced alongside the financial results.